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Open Access

Relationships between serum MCP-1 and
subclinical kidney disease: African AmericanDiabetes Heart Study
Mariana Murea1*†, Thomas C Register2†, Jasmin Divers3, Donald W Bowden4, J Jeffrey Carr5, Caresse R Hightower5,
Jianzhao Xu4, S Carrie Smith4, Keith A Hruska6, Carl D Langefeld3 and Barry I Freedman1*

Abstract
Background: Monocyte chemoattractant protein-1 (MCP-1) plays important roles in kidney disease susceptibility
and atherogenesis in experimental models. Relationships between serum MCP-1 concentration and early
nephropathy and subclinical cardiovascular disease (CVD) were assessed in African Americans (AAs) with type 2
diabetes (T2D).
Methods: Serum MCP-1 concentration, urine albumin:creatinine ratio (ACR), estimated glomerular filtration rate
(eGFR), and atherosclerotic calcified plaque (CP) in the coronary and carotid arteries and infrarenal aorta were
measured in 479 unrelated AAs with T2D. Generalized linear models were fitted to test for associations between
MCP-1 and urine ACR, eGFR, and CP.
Results: Participants were 57% female, with mean ± SD (median) age 55.6±9.5 (55.0) years, diabetes duration
10.3±8.2 (8.0) years, urine ACR 149.7±566.7 (14.0) mg/g, CKD-EPI eGFR 92.4±23.3 (92.0) ml/min/1.73m2, MCP-1
262.9±239.1 (224.4) pg/ml, coronary artery CP 280.1±633.8 (13.5), carotid artery CP 47.1±132.9 (0), and aorta CP
1616.0±2864.0 (319.0). Adjusting for age, sex, smoking, HbA1c, BMI, and LDL, serum MCP-1 was positively associated
with albuminuria (parameter estimate 0.0021, P=0.04) and negatively associated with eGFR (parameter estimate
−0.0003, P=0.001). MCP-1 remained associated with eGFR after adjustment for urine ACR. MCP-1 levels did not
correlate with the extent of CP in any vascular bed, HbA1c or diabetes duration, but were positively associated
with BMI. No interaction between BMI and MCP-1 was detected on nephropathy outcomes.
Conclusions: Serum MCP-1 levels are associated with eGFR and albuminuria in AAs with T2D. MCP-1 was not
associated with subclinical CVD in this population. Inflammation appears to play important roles in development
and/or progression of kidney disease in AAs.
Keywords: African Americans, Albuminuria, Atherosclerotic calcified plaque, Diabetes, GFR, MCP-1

Background
Inflammation, influx of circulating inflammatory cells,
synthesis and secretion of chemokines and cytokines
play important roles in diabetic kidney disease and atherosclerosis [1,2]. The relationship between serum chemokine monocyte chemoattractant protein-1 (MCP-1,
or CCL2) levels with kidney disease and subclinical cardiovascular disease (CVD) has not been evaluated in the
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African American (AA) population. Macrophages contribute to the pathophysiology of atherosclerosis, albuminuria, diabetic nephropathy (DN), and kidney failure
[3,4]. Macrophage trafficking and influx to the blood
vessel wall is driven in part by chemokines, and MCP-1
inhibition delays formation of atherosclerotic plaque [5].
In experimental and human DN, macrophages are the
principal infiltrating leukocyte population and the degree
of macrophage influx and MCP-1 expression in the
glomerular and interstitial compartments correlate with
albuminuria and kidney function outcome [4,6-8]. Experimentally, MCP-1 suppression ameliorated albuminuria and kidney interstitial disease [7].
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Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Albuminuria and kidney disease are strongly linked
with CVD. Presence of a graded association has been
demonstrated between estimated glomerular filtration
rate (eGFR) and albuminuria, with cardiovascular events,
mortality, and presence and severity of coronary artery
calcification (CAC) in European-derived populations
[9-11]. Despite presence of more severe conventional
CVD risk factors, AAs have markedly lower amounts of
CAC, carotid artery CP, and aorta CP than EAs [12,13],
along with significantly reduced rates of myocardial infarction when provided equal access to healthcare [14-16].
Relationships between conventional CVD risk factors and
subclinical CVD do not appear to differ by race, suggesting that novel risk factors including cytokines and genetic
variation may contribute to population-specific risks for
CP and CVD [17].
As inflammation has emerged at the core pathophysiology of both diabetic nephropathy and atherosclerosis,
we sought to investigate the relationships between serum
MCP-1 concentrations with albuminuria, kidney function, and vascular calcification in a well-characterized
cohort of AAs with type 2 diabetes (T2D) in the African
American-Diabetes Heart Study (AA-DHS). Previous
reports indicated that inflammation is a protracted
process, occurring from the early stages of nephropathy
(eGFR >90ml/min/1.73m2 and microalbuminuria) in
patients with type 1 diabetes (T1D) [18,19]. Presence of
inflammation in patients with chronic kidney disease
(CKD) has been associated with carotid intimal-medial
thickness [20] and increased risk of cardiovascular death
[21]. Similarly, vascular endothelial damage begins before it becomes clinically apparent, at early stages of kidney disease (GFR >90 ml/min/1.73m2) [22]. Elucidation
of inflammatory markers with impact on early kidney
disease and vascular dysfunction may guide innovative
therapies to prevent or reverse nephropathy and/or vascular damage. We hypothesized that serum MCP-1 concentration, a surrogate of systemic and vascular inflammation,
changes in T2D patients in relation to kidney function and vascular integrity. As such, the relationships
between serum MCP-1 concentrations with early diabetic nephropathy and vascular calcified plaque were
examined.

Methods
Study population

The AA-DHS is an observational study conducted on a
cohort of self-reported and unrelated AAs with T2D lacking advanced nephropathy. Participants with advanced
nephropathy or end-stage renal disease were excluded. Recruitment was conducted from internal medicine clinics
and community advertising, as previously published [23].
Briefly, participant examinations were conducted in the
Clinical Research Unit of Wake Forest Baptist Medical
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Center and included interviews for medical history and
health behaviors, anthropometric measures, resting blood
pressure (BP), electrocardiography, fasting blood sampling
(total cholesterol, low density lipoprotein [LDL] cholesterol, high density lipoprotein [HDL] cholesterol, triglycerides, hemoglobin A1c [HbA1c], glucose and high
sensitivity C-reactive protein [hsCRP]), spot urine collection for albumin:creatinine ratio (ACR), and computed tomography (CT).
History of CVD was provided by participant report
and medical record review. Individuals with a history
of myocardial infarction or stroke were included; however, CP scores in the coronary arteries were excluded
in participants who underwent prior coronary artery
bypass grafting and in the carotid arteries in participants who underwent carotid endarterectomy. We
assessed eGFR using the simplified MDRD study and
CKD-EPI equations [24,25]. Serum creatinine concentration was measured using a modified kinetic Jaffe method
and corrected for inter-laboratory differences and calibrated to the Cleveland Clinic [26]. Medications known
to influence atherosclerosis (lipid lowering medications)
and urine ACR (angiotensin-converting enzyme inhibitors [ACEi] and angiotensin-receptor blockers [ARB])
were recorded. The study was approved by the Institutional Review Board at the Wake Forest School of Medicine and all participants provided written informed
consent.

Vascular imaging

CP in the coronary arteries (CAC), carotid arteries
(CarCP), and infrarenal aorta (AorCP) were determined
using multidetector computed tomography (MDCT4)
with cardiac gating and capable of 500-millisecond temporal resolution using the segmented reconstruction algorithm (LightSpeed Qxi; General Electric Medical
Systems, Waukesha, WI, USA). Techniques for the coronary and carotid scans have been described in detail
[11]. In brief, participants were placed in the supine position on the CT couch over a quality control calibration
phantom (Image Analysis, Inc., Columbia, KY, USA) for
scans of the heart and abdomen. The abdomen scan
series was used to measure AorCP. Technical factors for
this series were: 120 kV, 250 mA, 0.8-second gantry rotation helical mode (7.5 mm/s), 2.5-mm slice thickness,
and standard reconstruction kernel. The display field of
view was 35 cm, resulting in a pixel dimension of 0.68
by 0.68 mm. CT scans of the three vascular territories
were analyzed on a G.E. Advantage Windows Workstation with the SmartScores software package (General
Electric Medical Systems) using a modified Agatston
scoring method, which adjusts for slice thickness and
uses the conventional threshold of 130 Hounsfield units.
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MCP-1 assay

Serum MCP-1 was measured using an enzyme-linked
immunosorbent assay (ELISA) (QuantikineW Human
CCL2/MCP-1 ELISA; R&D Systems, Minneapolis) in
freshly thawed serum samples which had been stored at
-80C since collection. Analyses were performed in
batches using ELISA kits from a single lot to minimize
variability due to manufacturing variation. Intra- and
inter-assay coefficients of variation for MCP-1 were
4.0%/3.4% at 62.5 pg/ml and 1.8%/2.1% at 500 pg/ml.
Statistical methods

Generalized linear models (GLM) were fitted to test for
associations between serum MCP-1 concentration and
diabetes duration, HbA1C, body mass index (BMI), urine
ACR, eGFR, CAC, CarCP and AorCP [27]. MCP-1
values greater than 486.7 pg/ml, corresponding to the
95th percentile in the distribution, were winsorized to
486.7 [28]. The Box-Cox method was applied to identify
the appropriate transformation best approximating the
distributional assumptions of conditional normality and
homogeneity of variance of the residuals [29]. This
method suggested taking the natural log of (CAC+1),
(CarCP+1) and (AorCP+1), (ACR+1), CRP, MDRD and
CKD eGFR, the inverse of HbA1c and the inverse square
root of BMI to minimize the influence of extremely large
covariate values on parameter estimates in the models.
No transformation was required for eGFR. GLM models
were fitted using the winsorized values of MCP-1 as the
dependent variable. After an unadjusted analysis, adjustments for age, sex, smoking, HbA1c, BMI, and LDL
levels were incorporated. Urine ACR was analyzed both
as categorical variable and as a continuous variable. The
models used to test for association between BMI and
HbA1c with MCP-1 contained one less variable than the
fully adjusted models between MCP-1 and other variables. Inter-active effects between BMI and MCP-1 on
kidney function measures were also performed. Interaction effects were evaluated by testing for the direct
interaction effect by including the centered product of
BMI by MCP-1 and performing the association analysis
between MCP-1 and the kidney function measures
stratified by BMI where the sample was stratified into
two subgroups (non-obese: BMI <30.0 kg/m2 and obese:
BMI ≥ 30.0 kg/m2). Type III sum of squares were also
computed to evaluate the effect of eGFR adjusted for
ACR (and vice-versa) and all other covariates on the vascular calcification and renal function measures.

Results
The study included 479 unrelated AAs with T2D (57%
women), 50.7% with hypertension (HTN), with mean ±
SD (median) age 55.6 ± 9.5 (55.0) years, diabetes duration 10.3 ± 8.2 (8.0) years, and BMI 35.5 ± 8.7 (34.0)

Page 3 of 9

kg/m2 (Table 1). Participants were stratified by baseline
urine ACR into non-albuminuric (urine ACR <30 mg/g;
n=300) and albuminuric (urine ACR ≥30 mg/g; n=179).
Characteristics of the cohort included serum MCP-1
levels 262.9 ± 239.1 (224.4) pg/ml, hsCRP 1.1 ± 1.8 (0.5)
mg/dl, MDRD eGFR 95.2 ± 27.2 (93.3) ml/min/1.73m2,
CKD-EPI eGFR 92.4 ± 23.3 (92.0) ml/min/1.73m2, and
urine ACR 149.7 ± 566.7 (14.0) mg/g. There were no between gender differences in serum MCP-1 levels (267.8 ±
242.0 (229.3) pg/ml in women, and 256.5 ± 235.4
(212.8) pg/ml in men, P=0.26). CAC was present in
62.7% of participants, 48.5% had detectable CarCP, and
77.9% detectable AorCP. CKD-EPI and MDRD determined eGFRs were highly correlated (Spearman correlation =0.93).
Subjects with albuminuria had a longer diabetes duration by mean ± SD 2.1 ± 0.2 years (P=0.0007), higher
prevalence of HTN (62% vs. 44%, P=0.0001), higher BP
values with mean ± SD difference of 8.9 ± 5.4 mmHg in
systolic BP (P<0.0001) and 2.9 ± 0.9 mmHg in diastolic
BP (P=0.008), and were more often prescribed ARB and
insulin (Table 1). Differences in biochemical parameters
were also noted, with the albuminuric group having
higher HbA1c, total cholesterol, triglycerides, and serum
creatinine; and lower fasting glucose and HDL (Table 2).
Modeled as a continuous variable, albuminuria was
negatively associated with eGFR (parameter estimates
and P-values of −0.0014 and 0.04 for CKD-EPI eGFR,
and −0.0015 and 0.06 for MDRD eGFR).
In the univariate analysis, serum MCP-1 levels had
negative association with Log (eGFR) and trended towards positive association with Log (urine ACR+1).
Adjusted models including demographic characteristics
(age, sex, smoking, BMI,) and laboratory values (HbA1c,
LDL) maintained significant evidence of negative association between MCP-1 and Log (eGFR) (parameter estimate −0.0003, P=0.001) and detected significant positive
association with urine ACR after logarithmic transformation (parameter estimate 0.0021, P=0.04) (Table 3).
Since urine ACR is associated with eGFR, we analyzed
the relationship between MCP-1 and eGFR based on
adjusting for Log (ACR+1), in a fully adjusted model.
Compared to ACR alone (parameter estimate −0.0135,
P=0.05), MCP-1 had the strongest association with
CKD-EPI eGFR (parameter estimate −0.0004, P=0.002)
(Table 4).
We next assessed whether there is a correspondence
between MCP-1, ACR, eGFR, and vascular CP. No association was detected between MCP-1 and CAC, CarCP,
or AorCP in either unadjusted or adjusted models
(Table 3). However, albuminuria was independently and
significantly associated with vascular CP in all three vascular beds, while eGFR did not exhibit an association
(Table 5).
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Table 1 Demographic characteristics of study participants by urine albumin: creatinine ratio
Variable

Urine ACR<30 (N=300)

Urine ACR≥30 (N=179)

ALL (N=479)

P-value

Mean

Median

SD

IQR

Mean

Median

SD

IQR

Mean

Median

SD

IQR

55.9

56.0

9.6

13.0

55.0

53.0

9.5

13.0

55.6

55.0

9.5

13.0

0.32

Diabetes duration (years)

9.5

7.0

8.2

8.0

11.6

10.0

8.0

8.0

10.3

8.0

8.2

8.0

0.0007

HTN n (%)

132

BMI (kg/m2)

35.5

34.1

8.5

10.0

35.6

33.6

9.2

11.3

35.5

34.0

8.7

10.6

0.83

Systolic BP (mm Hg)

129.9

129.0

16.2

21.0

138.8

137.0

21.6

27.5

133.2

132.0

18.9

24.0

<.0001

Diastolic BP (mm Hg)

76.5

76.0

10.9

14.5

79.4

80.0

11.8

16.0

77.6

77.0

11.3

15.0

0.008

Age (years)

(44.0)

111

(62.0)

243

(50.7)

0.0001

Smoking n (%)
Past

114

(38.0)

55

(30.7)

169

(35.3)

Current

61

(20.3)

51

(28.5)

112

(23.4)

0.08

ACEi n (%)

116

(38.7)

75

(41.9)

191

(39.9)

0.48

ARB n (%)

37

(12.3)

34

(19.0)

71

(14.8)

0.04

Lipid lowering med n (%)

148

(51.0)

93

(52.5)

241

(51.6)

0.75

Insulin n (%)

100

(33.3)

93

(52.0)

193

(40.3)

<0.0001

TZD n (%)

37

(12.3)

19

(10.6)

56

(11.7)

0.57

ACR, albumin: creatinine ratio; SD, standard deviation; IQR, interquartile range; BMI, body mass index; BP, blood pressure; ACEi, angiotensin- converting enzyme
inhibitor; ARB, angiotensin receptor blocker; HTN, hypertension; TZD, thiazolidinediones.

Relationships between serum MCP-1 with diabetes
duration, BMI, and hsCRP were also assessed. No correlations were observed between serum MCP-1 and diabetes duration or hsCRP. Serum MCP-1 levels correlated
with BMI, and this remained significant in the adjusted
model (P=0.01) (Table 3). To assess whether BMI
impacts the relationship between MCP-1 and kidney
function, association analyses were run with participants
stratified as obese (BMI ≥30.0) and non-obese (BMI

<30.0). We found no evidence of an interaction effect between BMI and MCP-1 on either eGFR or urine ACR. As
shown in Table 6, MCP-1 association parameters in
obese participants were similar to those in the non-obese
group (−0.0004 vs. -0.0004, P=0.75, for the interaction
effect on Log (eGFR); and 0.0017 vs. 0.0013, P=0.68,
for the effect on Log (urine ACR+1)). Evidence of an
association between MCP-1 and kidney function
remained significant in BMI stratified analyses, with

Table 2 Laboratory and imaging data by urine albumin: creatinine ratio
Variable

Urine ACR<30 (N=296)

Urine ACR≥30 (N=175)

ALL (N=471)

P-value

Mean

Median

SD

IQR

Mean

Median

SD

IQR

Mean

Median

SD

Fasting Glucose (mg/dl)

151.1

134

66.4

67

140.1

128

55.9

51

169.5

150

77.7

IQR
89

<.0001

HbA1c (%)

7.8

7.4

1.7

2.2

8.7

8.4

2.2

2.7

8.1

7.7

2.0

2.4

<.0001

Total Cholesterol (mg/dl)

175.9

169.0

41.0

52.0

189.5

180.0

56.1

62.0

181.0

174.0

47.6

56.0

0.01

HDL-Cholesterol (mg/dl)

49.2

47.0

13.8

16.5

45.3

43.0

13.1

16.0

47.8

46.0

13.6

17.0

0.0008

LDL-Cholesterol (mg/dl)

104.3

98.0

34.3

44.0

112.8

106.0

44.9

58.0

107.4

101.0

38.7

48.0

0.08

Triglycerides (mg/dl)

110.8

95.5

60.2

59.0

166.3

118.0

207.8

102.0

131.5

102.0

138.1

69.0

0.0001

Serum creatinine (mg/dl)

0.9

0.9

0.3

0.3

1.0

1.0

0.3

0.4

1.0

0.9

0.3

0.3

0.01

Serum Calcium

9.6

9.6

0.5

0.5

9.5

9.6

0.4

0.7

9.6

9.6

0.5

0.5

0.33

MDRD eGFR (ml/min)

96.6

93.9

26.3

30.6

92.8

92.3

28.5

38.4

95.2

93.3

27.2

33.6

0.15

CKD-EPI eGFR (ml/min)

93

92.0

21.9

32.4

91.3

92.6

25.5

44.6

92.4

92.0

23.3

35.8

0.53

Urine ACR (mg/g)

8.2

5.3

7.3

8.8

386.9

96.0

878.6

185.0

149.7

14.0

566.7

55.8

NA

hsCRP (mg/dl)

1

0.5

1.4

0.9

1.3

0.6

2.4

1.0

1.1

0.5

1.8

0.9

0.62

MCP-1 (pg/ml)

250.7

214.7

199.5

119.0

283.3

234.1

293.2

135.1

262.9

224.4

239.1

127.4

0.15

CAC (mass score)

222.7

4.5

518.0

170.0

377.8

32.3

784.7

351.8

280.1

13.5

633.8

235.5

0.001

CarCP (mass score)

43.2

0.0

132.8

22.0

53.7

2.3

133.1

44.5

47.1

0.0

132.9

33.0

0.01

AorCP (mass score)

1395

216.5

2426.0

1715.0

1990.0

380.0

3459.0

2301.0

1616.0

319.0

2864.0

1923.0

0.005

ACR, albumin: creatinine ratio; SD, standard deviation; IQR, interquartile range; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein;
eGFR, estimated glomerular filtration rate; hsCRP, high sensitivity C-reactive protein; MCP-1, monocyte chemoattractant protein-1; CAC, coronary artery calcied plaque;
CarCP, carotid artery calcified plaque; AorCP, infrarenal aorta calcified plaque.
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Table 3 MCP-1 associations in the unadjusted and fully adjusted models
Outcome

Unadjusted

Adjusted

Estimate

StdErr

P-value

Estimate

StdErr

P-value

Log(Diabetes duration)

0.00060

0.00033

0.07

0.0003

0.0003

0.34

1/(HbA1c)

2.71E-06

1.248E-05

0.83

−7.70E-06

1.23E-05

0.53

1/sqrt(BMI)

−1.37E-05

8.53E-06

0.11

−2.02E-05

8.28E-06

0.01

Log(hsCRP)

0.0003

0.0006

0.54

−0.0001

0.0007

0.87

Log(CAC+1)

0.0006

0.001

0.57

−0.0003

0.0015

0.82

Log(CarCP+1)

0.0001

0.0008

0.86

−0.0012

0.0011

0.31

Log(AorCP+1)

0.0013

0.0012

0.25

−0.001

0.0015

0.48

Log(Urine ACR+1)

0.0013

0.0007

0.09

0.0021

0.001

0.04

Log(MDRD eGFR)

−0.0005

0.0001

<.0001

−0.0005

0.0001

0.006

Log(CKD-EPI eGFR)

−0.0004

0.0001

<.0001

−0.0003

0.0001

0.001

MCP-1, monocyte chemoattractant protein-1; HbA1c, hemoglobin A1c; BMI, body mass index; hsCRP, high sensitivity C-reactive protein; CAC, coronary artery
calcified plaque; CarCP, carotid artery calcified plaque; AorCP, infrarenal aorta calcified plaque; ACR, albumin: creatinine ratio; eGFR, estimated glomerular
filtration rate.
Adjusted model includes age, sex, smoking, HbA1c, BMI, and LDL-cholesterol.

meta-analysis P-value = 0.001 for Log (eGFR) and 0.04
for Log (urine ACR+1).

Discussion and conclusion
This large cross-sectional study characterized relationships between serum MCP-1, albuminuria, eGFR and
CP in the understudied AA population with T2D. After
adjusting for covariates, higher serum MCP-1 levels
associated positively with albuminuria and negatively
with eGFR. In contrast, serum MCP-1 did not independently associate with atherosclerosis and subclinical CVD
measured as CP, suggesting differential molecular relationships between inflammation, risk for kidney disease,
and CVD in AAs with T2D.
The pathophysiologic connection between atherosclerosis, CAC, albuminuria and kidney dysfunction is poorly
understood at the molecular level. Previous studies
demonstrated that MCP-1 is involved in the pathophysiology of atherosclerosis and DN in T1D and T2D [5,7].
MCP-1 is synthesized and secreted by a myriad of cells
(monocytes, macrophages, endothelial cells, renal
mesangial and tubular cells); and both tissue and systemic cells can contribute to detectable serum MCP-1
levels. In the hyperglycemic milieu, MCP-1 is produced
by resident renal endothelial cells, mesangial cells,
Table 4 Association between MCP-1, eGFR, and ACR in
the fully adjusted model
Dependent

Parameter

Estimate

StdErr

P-value

Log(MDRD eGFR)

MCP-1

-0.0004

0.0001

0.002

Log(MDRD eGFR)

Log(ACR+1)

-0.0133

0.0078

0.08

Log(CKD-EPI eGFR)

MCP-1

-0.0004

0.0001

0.002

Log(CKD-EPI eGFR)

Log(ACR+1)

-0.0135

0.0072

0.05

MCP-1, monocyte chemoattractant protein-1; eGFR, estimated glomerular
filtration rate; ACR, albumin: creatinine ratio.
Covariates included in the model are age, sex, smoking, HbA1c, BMI, and LDL.

podocytes, and tubular epithelial cells; as well as by circulating or infiltrating monocytes/macrophages [30].
Several reports attest to the positive correlation between
tissue MCP-1 expression and urine levels with albuminuria, mesangial proliferation, and interstitial fibrosis in a
wide range of kidney diseases in humans [8,31-36]. In
small studies comprised of European-derived participants with T1D or T2D, ELISA-based measurements of
serum MCP-1 did not correlate with albuminuria
[30,34]. It has been proposed that while the histopathology in diabetic kidney disease has remarkable similarity between type 1 and type 2 diabetes, and between
population groups, the pathogenetic background may
differ between AAs and EAs, and T2D or T1D [37].
Other longitudinal studies comprised of EAs with T1D,
found that urine MCP-1 levels were significantly higher
in patients with early nephropathy (GFR<90 ml/min and
microalbuminuria) relative to those without nephropathy, with no difference in serum MCP-1 levels. [18,19]
Relative to EAs, it is possible that inflammatory pathways are upregulated in AAs. Previous studies have
shown that AAs have higher serum CRP and
interleukin-6 (IL-6) concentrations and display heightened oxidative stress and inflammation based on
in vitro human umbilical vein endothelial cells
(HUVECs) studies [38,39]. It is biologically plausible that
MCP-1 may play differential roles in the pathophysiology of DN based on the type of diabetes and ethnic
background.
We originally postulated that inflammation is a common mediator for both subclinical kidney disease and
CVD in AAs with T2D and that systemic MCP-1 levels
would correlate with markers of kidney disease and atherosclerosis. We found that a higher burden of vascular
calcification was present in those with albuminuria, but
CP did not associate with serum MCP-1 levels. Other
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Table 5 Type III mean squares and association between CP, ACR, and MCP-1
Dependent

Model

Predictor

Estimate

StdErr

P-value

CAC

ACR + all covariates in the adjusted model

Log(ACR+1)

1.5E-01

6.6E-02

0.02

eGFR + all covariates in the adjusted model

eGFR

1.7E-04

4.3E-03

0.96

ACR and MCP-1 + all covariates in the adjusted model
eGFR and MCP-1+ all covariates in the adjusted model
ACR, eGFR and MCP-1+ all covariates in the adjusted model

CarCP

1.5E-01

6.6E-02

0.02

-1.7E-04

1.1E-03

0.87

eGFR

2.0E-04

4.4E-03

0.96

MCP-1

6.0E-05

1.1E-03

0.95

eGFR

6.9E-04

4.4E-03

0.87

Log(ACR+1)

1.5E-01

6.6E-02

0.02

MCP-1

-1.4E-04

1.1E-03

0.89

ACR + all covariates in the adjusted model

Log(ACR+1)

1.1E-01

5.1E-02

0.02

eGFR + all covariates in the adjusted model

eGFR

-4.3E-03

3.4E-03

0.20

ACR and MCP-1 + all covariates in the adjusted model

Log(ACR+1)

1.1E-01

5.2E-02

0.02

MCP-1

3.3E-05

8.5E-04

0.96

eGFR

-4.2E-03

3.4E-03

0.21

MCP-1

5.7E-05

8.6E-04

0.94

eGFR and MCP-1+ all covariates in the adjusted model
ACR, eGFR and MCP-1+ all covariates in the adjusted model

AorCP

Log(ACR+1)
MCP-1

eGFR

-3.9E-03

3.4E-03

0.25

Log(ACR+1)

1.1E-01

5.2E-02

0.03

MCP-1

-1.1E-04

8.6E-04

0.90

ACR + all covariates in the adjusted model

Log(ACR+1)

1.9E-01

6.9E-02

0.005

eGFR + all covariates in the adjusted model

eGFR

-5.2E-03

4.4E-03

0.24

ACR and MCP-1 + all covariates in the adjusted model

Log(ACR+1)

1.9E-01

6.9E-02

0.006

MCP-1

6.4E-04

1.1E-03

0.56

eGFR and MCP-1+ all covariates in the adjusted model
ACR, eGFR and MCP-1+ all covariates in the adjusted model

eGFR

-4.8E-03

4.5E-03

0.28

MCP-1

7.7E-04

1.1E-03

0.49

eGFR

-4.2E-03

4.5E-03

0.34

Log(ACR+1)

1.9E-01

6.9E-02

0.007

MCP-1

4.9E-04

1.1E-03

0.66

CP, calcified plaque; ACR, albumin: creatinine ratio; eGFR, estimated glomerular filtration rate; MCP-1, monocyte chemoattractant protein-1; CAC, coronary artery
calcified plaque; CarCP, carotid artery calcified plaque; AorCP, infrarenal aorta calcified plaque.
The covariates included in the adjusted model are age, sex, smoking, HbA1c, BMI, and LDL.

studies demonstrated that serum MCP-1 levels correlate
with CVD outcomes following acute coronary events, independent of traditional CVD risk factors [40]. Nevertheless, these studies did not examine the effect of
serum MCP-1 on CV events based on kidney function
or independent of the association with urine albumin excretion and eGFR. As in the present report, a large
population-based sample from the Dallas Heart

Study did not observe an association between serum
MCP-1 and CAC after adjusting for age and other
covariates [41].
This is the first report of which we are aware detecting
associations between serum MCP-1 with albuminuria
and eGFR in AA patients with T2D and early nephropathy. Study participants were AAs without advanced kidney disease and no differences in serum MCP-1 levels

Table 6 Fully adjusted MCP-1 associations stratified by BMI
CKD-EPI eGFR
N

Urine ACR

Estimate

StdErr

P-meta

P-inter

Estimate

StdErr

P-meta

P-inter

0.001

0.75

0.0017

0.0015

0.04

0.68

0.0013

0.0009

BMI < 30.0

134

-0.0004

0.0002

BMI ≥ 30.0

345

-0.0004

0.0001

eGFR, estimated glomerular filtration rate; ACR, albumin: creatinine ratio; BMI, body mass index.
Results were adjusted for age, sex, smoking, HbA1c, and LDL-cholesterol.
eGFR and ACR values were logarithmically transformed.
P-meta is the P-value observed between MCP-1 and each outcome stratified by BMI.
P-inter is the interaction P-value for the association difference between MCP-1 and each outcome in each BMI subgroup.
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were seen across genders. The nature of the factors determining elevated concentrations of serum MCP-1 in
patients with T2D and early DN remains unknown. It is
possible that high MCP-1 expression in the interstitial
kidney macrophages leads to elevated systemic levels of
MCP-1 proportional to the inflammatory and nephropathy stage. Another possibility, not mutually exclusive, is
that serum MCP-1 levels are elevated in patients with
early nephropathy due to dysregulated activation of systemic leukocytes. Indeed, several studies confirm an aberrant production of inflammatory cytokines and
chemokines by circulating lymphocytes and monocytes
in T2D patients with nephropathy [42]. Decreased filtration of extra-renally synthesized MCP-1 is less likely,
since a minority of participants had an eGFR below
60 ml/min/1.73m2.
In addition to roles of MCP-1 in atherosclerosis and
kidney disease, several studies implicated MCP-1 in the
pathophysiology of obesity and insulin resistance [43,44].
In our sample of AAs with T2D, significant correlations
were observed between MCP-1 and BMI, but not with
diabetes duration or HbA1c. The association between
adipose tissue and MCP-1 raised the question whether
the link between serum MCP-1 and renal function parameters could have been driven by the high prevalence of
obesity in this cohort. Adjustment for BMI and cholesterol failed to modify the association and BMI-stratified
effect sizes were not statistically different between obese
and non-obese strata. As such, relationships between
serum MCP-1 and kidney function were not impacted
by obesity.
Significant relationships between MCP-1 with eGFR
and albuminuria, coupled with lack of association with
CP, imply that MCP-1 does not mediate joint pathways
implicated in co-existing kidney and CVD. However, the
lack of a cross-sectional association between MCP-1 and
burden of CP in AAs does not exclude a role for this
molecule in the inflammatory component of atherosclerosis. Previous studies have shown that serum MCP-1
levels are higher in patients with active angina (compared to those with stable coronary disease), and higher
levels predicted future coronary events and mortality following an acute coronary event [45,46]. In addition,
serum MCP-1 levels have been associated with immunohistochemical indices of inflammation and matrix remodeling in the coronary atherosclerotic plaques of
non-human primates [47]. The role of MCP-1 in CP
should also be explored in EAs, a population with higher
burden of vascular calcification than AAs [12,13].
This study has important strengths and some limitations. AAs are known to display different patterns of
nephropathy and CVD morbidity relative to EAs. The
large and well phenotyped AA sample enabled simultaneous evaluation of a molecular biomarker potentially
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impacting albuminuria, eGFR, and subclinical atherosclerosis. Preserved kidney function in AA-DHS participants lessens concern that altered serum MCP-1 levels
were due to kidney failure, whether mediated by poor
renal excretion or inflammation-driven overproduction.
Limitations include the cross-sectional nature of study
measurements, rendering inability to secure a causal relationship between MCP-1 and early DN. Longitudinal
studies characterizing relationships between MCP-1 and
albuminuria and eGFR are warranted and could provide
support for pharmacological MCP-1 inhibition during
the incipient stages of DN [48]. Recent studies in mouse
models suggest such treatment has promise [49].
In conclusion, MCP-1 serum concentrations manifest
positive association with albuminuria and negative association with eGFR in AAs with T2D; without association
with subclinical atherosclerosis. Relationships between
MCP-1, albuminuria, eGFR, and vascular CP need to be
evaluated in EAs and non-diabetic AAs. MCP-1 inhibition could provide a novel therapeutic strategy to prevent diabetic kidney disease in AAs with T2D.
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